2 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
Follow Malignant Solid Neoplasm: new trials by email Literature Review of Malignant Solid Neoplasm trials Research Report on Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Itacitinib, Corticosteroid, Endoscopic Procedure - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Withdrawn | Douglas Johnson | 2023-03-03 | 2026-04-27 | |
| Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year Lopinavir/Ritonavir, Placebo Administration, Questionnaire Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2021-05-01 | 2021-04-26 |
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Site (2)
Adrenal Cortex Hormones (1) · Endoscopy (1) · Lopinavir (1) · itacitinib (1) · lopinavir-ritonavir drug combination (1)
Douglas Johnson (1) · OHSU Knight Cancer Institute (1)
Douglas Johnson, MD (1) · Jennifer Saultz (1)